AUAUniversity Podcast Series: Episode No. 81

GU Podcast (2020) - Sequencing Of Agents And Combination Of Treatment Options For RCC

At the conclusion of this activity, participants will be able to:

1. Explain the sequencing of novel therapies and be able to identify patient progression of disease.
2. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer.

This educational series is supported by independent educational grants from:
Astellas
AstraZeneca
Bristol Myers Squibb
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Merck
Pfizer, Inc
Sanofi Genzyme
UroGen Pharma, Inc.